12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea Published
The Annals of Internal Medicine has published the full 12-month results of LivaNova’s OSPREY randomized controlled trial, which assessed the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS) using the aura6000™ System for treating moderate obstructive sleep apnea.
LONDON–(BUSINESS WIRE)—- $LIVN #livn–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company’s OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova’s aura6000™ System for the treatment of mod